ERBB2 and adenocarcinoma: Our immunotherapy approach originates from a series of studies, in which T cells have been redirected to EpCam on adenocarcinomas [3]; HER2/neu on prostate [7], breast [6], and ovarian cancer [5]; EGFR on a variety of tumor types [4]; and CD20 on malignant B cells [7].